Table 2.
Comparison of clinical features between patients with relapse and without relapse.
| Relapse-free n=70 |
Relapsed n=23 |
P | |
|---|---|---|---|
| Onset age (median (IQR), years) | 5.7(4.5) | 6(3.5) | 0.170 |
| Interval from onset to diagnosis (median (IQR), days) | 19(14) | 20(350) | 0.008 |
| Laboratory investigation outcome | |||
| CSF WBC (median (IQR), x106/L) | 40(80) | 29(69) | 0.786 |
| CSF Protein (median (IQR), g/L) | 0.36(0.21) | 0.44(0.33) | 0.705 |
| MOG antibody titer (median (IQR)) | 32(90) | 100(288) | 0.000 |
| Duration of persistent MOG antibody positive (median (IQR), months) | 3(3) | 24(12) | 0.000 |
| OCB (N (%)) | 8(11.4) | 2(8.7) | 1.000 |
| Anti-NMDAR antibody (Positive, N (%)) | 7(10) | 4(17.4) | 0.456 |
| MRI Lesion size (>2cm, N (%)) | 49(70) | 18(78.3) | 0.444 |
| Gadolinium enhancement MRI lesions (N (%)) | 25(35.7) | 12(52.2) | 0.162 |
| EDSS at onset (median (IQR)) | 6.5(3) | 6(2.5) | 0.676 |
| EDSS after acute treatment (median (IQR)) | 2(1) | 2(1) | 0.115 |
| Duration of follow-up (median (IQR), months) | 10(17) | 24(35) | 0.002 |
| EDSS at last follow-up (median (IQR)) | 0(1) | 1(2) | 0.009 |
| Sequalae (N (%)) | 24(34.3) | 15(65.2) | 0.009 |
CSF, cerebrospinal fluid; EDSS, Expanded Disability Status Scale; IQR, interquartile range; MOG, myelin oligodendrocyte glycoprotein; MRI, magnetic resonance image; NMDAR, N-methyl-D-aspartate receptor; OCB, oligoclonal bands; WBC, white blood cell.